Inclusion Criteria:

1. Patients with histologically confirmed epithelial ovarian cancer, primary peritoneal
carcinomatosis or fallopian tube cancer

2. Patients must have platinum resistant (relapse-free interval < 6 months of a
platinum-containing primary or secondary therapy) or platinum refractory (progression
during primary or secondary platinum treatment) disease defined by measurable disease
according to RECIST or elevated CA-125 level according the GCIG-criteria.

Definition of relapse: Demonstration of measurable or non-measurable tumour according
to RECIST criteria by an imaging procedure (where applicable before relapse surgery)
or increase in the tumour marker CA-125 to twice the upper laboratory value of normal
for the hospital or histological confirmation of tumour relapse by biopsy or surgery.

3. No more than 2 prior treatment regimens for recurrent epithelial ovarian cancer.

4. Elevated CA-125-value before study entry in order to assess the response according
the GCIG-criteria (see below). Patients without elevated CA-125 may be enrolled if
they show a measurable or not-measurable disease (according RECIST) evaluated by
imaging techniques (measurable disease - at least one unidimensionally measurable
lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan) or
histologically or cytologically confirmed relapse

5. ECOG Performance Status of 0 or 1

6. ≥ 18 years age

7. The patient must be recovered from a prior operation. The operation must be performed
at least 4 weeks prior to start of study drug,

8. Adequate bone marrow, liver and renal function as assessed by the following
laboratory requirements to be conducted within 7 days prior to screening

- Hemoglobin ≥ 9.0 g/dl

- Leucocyte count ≥ 3.000/micro liter

- Absolute neutrophil count (ANC) major than 1.500/micro liter

- Platelet count ≥ 100.000/micro liter

- PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically
anticoagulated with an agent such as coumadin or heparin will be allowed to
participate provided that no prior evidence of underlying abnormality in these
parameters exists].

- Total bilirubin < 1,0 times the upper limit of normal

- ALT and AST < 2,5 x upper limit of normal (< 5 x upper limit of normal for
patients with liver involvement of their cancer); Alkaline phosphatase < 4 x ULN

- Calculated creatinine clearance ≥ 50 ml/min or serum creatinine ≤ 1,2 x upper
limit of institutional values (according to Cockcroft and Gault)

9. Life expectancy of at least 12 weeks

10. Signed and dated written informed consent before the start of specific protocol
procedures.

Exclusion Criteria:

1. History of cardiac disease: congestive heart failure >NYHA class 2; active coronary
artery disease (CAD) or myocardial infarction within the past 6 months (MI more than
6 months prior to study entry is allowed); cardiac arrhythmias requiring
anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled
arterial hypertension with systolic blood pressure >160 mmHg or diastolic blood
pressure > 90 mm Hg despite optimal treatment

2. Previous or concurrent cancer that is distinct in primary site or histology from the
cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively
treated > 5 years prior to study entry

3. Prior radiological or clinical evidence of CNS metastases including previously
treated, resected, or asymptomatic brain lesions or leptomeningeal involvement by
head CT scan or MRI

4. Known or suspected hypersensitivity reaction to topotecan or any ingredient of
topotecan or sorafenib or any ingredient of sorafenib

5. Active clinically serious infections (> grade 2 NCI-CTC version 3.0)

6. History of HIV infection or chronic hepatitis B or C

7. History of organ allograft

8. Patients with history of colon perforation

9. Patients with history of colitis or neutropenia colitis

10. Patients with evidence or history of bleeding diathesis

11. Serious non healing wound, fracture or ulcer

12. Patients undergoing renal dialysis

13. Patients unable to swallow oral medications

14. Significant disease which, in the investigator's opinion, would exclude the patient
from the study

15. Substance abuse, medical, psychological or social conditions that may interfere with
the patient's participation in the study or evaluation of the study results

16. Patients with seizure disorder requiring medication (such as steroids or
anti-epileptics)

17. Medical or psychological conditions that would not permit the subject to complete the
study or sign informed consent

18. Any condition that is unstable or could jeopardize the safety of the patient and
their compliance in the study

19. Legal incapacity or limited legal capacity

20. Participation in another clinical study with experimental therapy within the 30 days
before start of treatment

21. Subjects housed in an institution on official or legal orders.

Excluded therapies and medications, previous and concomitant:

22. Patients with prior therapy containing topotecan

23. Patients with prior therapy containing Avastin or other VEGFR TK1

24. Any other anticancer chemotherapy or immunotherapy or investigational drug therapy
outside of this trial during the study or within 4 weeks prior to study entry.

25. Radiotherapy during study or within 4 weeks prior to start of study drug and prior
radiotherapy of > 25% of the bone marrow (exception: palliative radiotherapy of
non-target lesions or pain therapy or local bone irradiation)

26. Autologous bone marrow transplant or stem cell rescue within 4 months of study